Good morning, HealthTech insiders. Three hours in a clinic after every injection. That has been one of the biggest obstacles to long-acting olanzapine. Teva just won FDA approval for Weltruza, a once-monthly shot given under the skin that requires no post-injection monitoring. For patients and clinics, the breakthrough is easy to understand: a familiar schizophrenia medicine with a much smaller appointment burden.
And that is only one of three very different treatment barriers in today's Signal. argenx reported encouraging Phase 2 results for a celiac antibody designed to protect the intestine during gluten exposure. CraniUS announced another cranial-plate clearance and a patent for a separate, investigational system intended to deliver medicines directly into the brain. Different diseases, different stages of development, but the same question underneath them: what changes when getting treatment to the right place becomes easier?
In today's Signal:
Teva's monthly olanzapine breakthrough: Weltruza wins FDA approval for adults with schizophrenia, without loading doses, oral supplementation, or required post-injection monitoring.
A celiac drug moves forward: argenx's FB102 met its Phase 2 intestinal-damage endpoint during a controlled gluten challenge; Phase 3 development is planned.
CraniUS builds toward brain delivery: NeuroPASS 2 is a cleared cranial plate. NeuroPASS 3, the patented drug-delivery program, remains investigational.
What We're Watching Next: Psychiatric clinic adoption, celiac trial design, and the evidence needed to move brain-delivery hardware into human studies.
In partnership with
Elon's new company is private. These 3 tickers aren't.
The next Apple may already exist. Insider sources say Elon has spent two years building a secret device inside Tesla's facilities — one he claims will be "10x bigger than the largest product in history."
There's just one problem: the company is private, and unless you know Elon personally, you can't buy a single share. That was true until Guardian's research team found three public ticker symbols sitting in the launch supply chain.
Click here to see all 3 tickers, free of charge.
You won't hear these names on CNBC — Wall Street hasn't published a word on the connection. But when the launch hits September 21, that quiet ends.
Some are already calling this the biggest opportunity since AI. For anyone who missed Apple before the iPhone, this may be a second look at that kind of setup.
LATEST DEVELOPMENTS
NEUROPSYCHIATRY & DRUG DELIVERY
1. FDA Approves Teva's Weltruza, a Monthly Olanzapine Shot Without Required Post-Injection Monitoring
Image: Teva Pharmaceuticals
Teva announced FDA approval on October 9 for Weltruza, the first once-monthly subcutaneous olanzapine formulation for adults with schizophrenia. It uses Medincell's SteadyTeq technology and is expected to become available in the United States in the coming weeks.
The details:
A simpler visit: No loading doses, oral supplementation, or post-injection monitoring are required. Older intramuscular olanzapine, Zyprexa Relprevv, requires at least three hours of observation after each injection.
Clinical foundation: Approval follows the Phase 3 SOLARIS program. Weltruza comes in three strengths: 318 mg, 425 mg, and 531 mg, corresponding to daily oral doses of 10 mg, 15 mg, and 20 mg.
Safety still matters: Weight gain, metabolic changes, and injection-site reactions remain relevant. Teva's safety information says it is not known whether post-injection delirium/sedation syndrome can occur with Weltruza; removing the observation requirement does not establish zero risk.
The Signal: A formulation change can alter the practical reach of an established medicine. Removing a lengthy observation window could make olanzapine injections easier to offer in community psychiatry. The commercial test is whether coverage, procurement, and patient follow-through allow clinics to turn that simpler visit into sustained treatment access.
CLINICAL IMMUNOLOGY & GASTROENTEROLOGY
2. argenx's FB102 Meets a Phase 2 Celiac Endpoint, With Phase 3 Development Planned
Image: argenx
argenx reported positive topline results on October 8 for FB102, an investigational antibody targeting CD122. The study tested whether it could protect the intestine during deliberate gluten exposure, a meaningful development for a disease still managed with a strict gluten-free diet.
The details:
The study: FB102-301 enrolled 126 adults whose disease was controlled on a gluten-free diet. Participants received intravenous FB102 or placebo during an eight-week gluten challenge.
The primary result: The drug met the Day 78 endpoint measuring change in villus height-to-crypt depth versus placebo (p=0.0176). Other inflammatory and symptom measures were consistent with that finding, according to argenx.
The next step: Phase 3 development is planned. Detailed results are still to be presented, and the medicine remains investigational; this is not approval or evidence that patients can abandon dietary precautions.
The Signal: Protecting intestinal tissue is a more consequential goal than making gluten exposure feel less uncomfortable. But the next trial must establish how reliably that protection holds, how symptoms change, and how safety performs over longer treatment. The opportunity is substantial; the evidence is still developing.
INTERVENTIONAL NEUROTECH & DRUG DELIVERY
3. CraniUS Announces a Second Cranial-Plate Clearance and a Patent for Investigational Brain Delivery
Image: CraniUS Therapeutics
CraniUS announced two separate milestones on October 7: FDA clearance for NeuroPASS 2, a new CraniUS Plate configuration, and a patent covering the architecture behind its NeuroPASS 3 drug-delivery program.
The details:
What is cleared: FDA decision K262874, dated September 11, covers the patient-specific cranial plate. Its opening is designed to accommodate a future intracranial pressure sensor; the sensor and monitoring function are not cleared as part of this device.
What is patented: U.S. Patent No. 12,752,051 covers an architecture combining a cranial implant, refillable reservoir, regulated pump, and brain-delivery catheters. Patent protection establishes intellectual-property rights, not clinical effectiveness.
What remains ahead: NeuroPASS 3 is an investigational, drug-led combination product. It is not FDA-cleared or approved and is not available for sale. The company is targeting a first-in-human study in Q2 2027.
The Signal: CraniUS is trying to turn cranial reconstruction into a foundation for therapeutic access. That is an interesting platform strategy, but plate clearance and drug-delivery validation are different hurdles. The next meaningful evidence will concern distribution, long-term reliability, safety, and the treatment paired with the device.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
Weltruza's route into community clinics: Formulary decisions, ordering logistics, and the first real-world adoption reports will show whether reduced appointment burden translates into wider access.
FB102's Phase 3 design: Watch for trial registration, treatment duration, patient selection, and the balance between tissue-protection and symptom endpoints. A controlled gluten challenge leaves important questions about everyday use.
NeuroPASS 3's move toward human testing: Nonclinical evidence, regulatory authorization, and a registered clinical protocol will matter more than another hardware headline. Q2 2027 is a company target, not a confirmed study start.
💰 FOLLOW THE MONEY
The deals:
Sava: $36M Series B led by Ascensia Diabetes Care, plus a European commercialization and distribution agreement for its developing glucose microsensor.
Wally: $25M Series A led by Maveron to expand subscription oral care, with Bling Capital and angel investors including Jack Abraham participating.
AblePay: $20M Series A led by F-Prime, with A1 Health Ventures and .406 Ventures, to expand healthcare affordability and patient-payment services.
The pattern: These three rounds total $81M, backing businesses that aim to make routine care easier to use: less intrusive glucose monitoring, simpler preventive dental access, and more manageable medical bills. The shared investment thesis is practical, but the execution risks differ. Sava still needs pivotal evidence and regulatory authorization; Wally must scale clinics; AblePay must expand provider relationships and payment performance.
📆 UPCOMING HEALTHTECH EVENTS
Frontiers Health 2026: Oct 20–21, 2026 | bcc Berlin Congress Center, Berlin, Germany
Digital health leaders will examine AI-enabled health systems, adoption, reimbursement, and the next phase of care delivery.Global Health Exhibition 2026: Oct 26–29, 2026 | Riyadh Exhibition & Convention Centre, Malham, Saudi Arabia
A major gathering for healthcare investment, medical technology, and health-system transformation in Saudi Arabia and beyond.HLTH USA 2026: Nov 15–18, 2026 | The Venetian Expo, Las Vegas, Nevada
Providers, payers, founders, investors, and policymakers meet around healthcare innovation, AI, and business strategy.
🛠️ Trending HealthTech AI Tools
🩺 Tempus ECG-PH: FDA-cleared software that flags ECG signs associated with pulmonary hypertension in symptomatic adults aged 40 and older without a known PH history. It supports further evaluation; it is not a general asymptomatic screening test.
🫀 Heartvue.Proton: FDA-cleared cardiac MRI processing and measurement software with an authorized Predetermined Change Control Plan. Clinicians can review and edit automated results; permitted updates must stay within the cleared plan.
🩻 DeepHealth Chest XRay: FDA-cleared computer-aided detection built on a foundation model, supporting radiologists by locating suspected nodules, consolidation, mediastinal/hilar abnormalities, and pleural-space abnormalities.
🛠️ Trending HealthTech AI Startups
📱 Sava: Developing a wearable microsensor platform, starting with glucose. The latest funding supports manufacturing and clinical work ahead of a potential European launch; additional biomarkers remain a development ambition.
🦷 Wally: Combines subscription preventive dental care with digital diagnostics and AI-supported workflows, aiming to make repeat hygiene visits easier to access without traditional insurance.
💳 AblePay: A healthcare affordability platform offering flexible patient-payment options and faster, non-recourse payment for participating providers.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
Beyond the Three-Hour Wait: What Weltruza Changes for Community Psychiatry
How a different olanzapine formulation could reshape clinic capacity, and why reimbursement and safety follow-up still matter.Beyond Gluten Avoidance: What FB102's Phase 2 Result Does, and Does Not, Show
The intestinal-protection evidence behind argenx's celiac program and the questions its next trial needs to answer.From Cranial Reconstruction to Brain Delivery: The Two Stages of CraniUS's NeuroPASS Strategy
Why a cleared cranial plate and a patented investigational pump must be assessed separately, and what would validate the platform.
Which of today's advances could make the biggest difference to treatment access?
That's it for today!
A medicine can work and still be difficult to deliver.
Today's stories show three ways developers are trying to close that gap: simplify the visit, protect tissue from a recurring trigger, or build a new route to a difficult target.
They are also at very different stages. Weltruza has an approval. FB102 has a promising Phase 2 result. NeuroPASS 3 has a development program and a patent.
The real test is what happens next: can each advance make treatment easier to access while producing evidence that it improves care?
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal